Meridian Bioscience Sets a New Sustainability Standard in Diagnostic Assay Development with the Launch of Two New Animal-Free Immunoassay Interference Blockers

Un­der new CEO Bill An­der­son, Bay­er re­mains com­mit­ted to be­com­ing a top 10 on­col­o­gy play­er, and the road to do­ing so will be paved by

Out of hun­dreds of po­ten­tial drugs with rare pe­di­atric dis­ease des­ig­na­tions, on­ly 7% of them have won pri­or­i­ty re­view vouch­ers from the FDA, ac­cord­ing to